Mayo Clinic researchers are working to accelerate the diagnoses of rare diseases and renew hope for patients whose symptoms have defied an explanation ― sometimes for years or even decades.
The team of genomics experts has developed an automated system called RENEW for tracking new scientific knowledge from around the world of pathogenic genetic variants and applying it to Mayo Clinic patients with rare and undiagnosed diseases. RENEW stands for reanalysis of negative whole-exome/genome data.
"We're seeing dramatic growth in knowledge around what causes genetic disease, so we wanted to create a system to consistently track these discoveries," says Eric Klee, Ph.D., a Mayo Clinic bioinformatics scientist within the Center for Individualized Medicine.
An estimated 300 million people worldwide have a rare disease, research has found. Rare diseases can be chronic, debilitating and even deadly. Many rare diseases are caused by mutations in genes or chromosomes ― either passed from a parent or occurring randomly in a single person. In some instances, patients with rare diseases search for answers for 10 years or longer, propelled through a marathon of health care provider visits and tests.
Reanalyzing rare disease cases through discovery hub
The launch of RENEW comes at a pivotal time when advancements in genomic sequencing technologies and bioinformatics tools are leading to a greater understanding of the links between genes and disease. Last year alone, researchers within Mayo Clinic and across the globe documented nearly twice as many newly discovered gene-disease variants, compared to five years ago.
Similarly, over just three months, approximately 8,400 new genetic variants were described in one public database alone, and more than 260,000 previously known variants were updated with new information.
Dr. Klee says, with RENEW, the latest worldwide gene-disease findings are automatically downloaded every three months from a hub of published discoveries, including from the Human Gene Mutation Database, ClinVar and Online Mendelian Inheritance in Man. New findings are then compared to Mayo's database of patient sequencing results to identify potentially important developments.
"We're able to identify any differences within minutes and then apply those differences to patient data to see if any patients have these new emerging findings," Dr. Klee says.
A key feature of RENEW is a special set of filters that whittle down the new genetic information available since the last analysis and zero in on what could cause the disease.
Alejandro Ferrer, Ph.D., the co-developer of RENEW, uses key pieces of information that allow the system to tailor the filters to each patient's specific characteristics. Dr. Ferrer is a translational omics researcher in Mayo Clinic's Center for Individualized Medicine and Division of Hematology.
"The filter allows only the relevant information to pop up, so new genes and variants that have been added to the database are flagged, as well as important changes to information on known disease-causing genes and variants," Dr. Ferrer explains. "We don't start with a case from scratch. We're building up from the last time that we analyzed the case, and we just focus on what is new."
Dr. Ferrer says the most obvious advantage of this approach is the enormous amount of time and effort it saves.
"Usually, reanalyzing a case takes researchers and clinicians hours or days to sift through published papers that describe new gene-disease links and going through complex patient data to search for clues," Dr. Ferrer says.
The researchers emphasize RENEW does not replace the manual process but rather gives it a boost. So far, they say the results are encouraging.
"Solving a case does not always come with an actionable therapeutic option, but providing patients with an answer to what is the cause of their disease is the most important first step toward finding a treatment," Dr. Klee says.
Mayo Clinic investigated approximately 700 rare disease cases in 2021, providing a conclusive diagnosis to nearly one-third of patients, including 14 patients with newly discovered gene-disease associations.
"As scientific understanding continues to expand, my hope is that by reanalyzing data periodically, we can potentially help more people find answers," Dr. Klee says. “We are committed to continue exploring and implementing new approaches to benefit our patients.”
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Susan Murphy, Mayo Clinic Public Affairs, email@example.com
© Press Release 2022
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.